Circle Pharma to Present Cyclin D1 RxL Inhibition Data Showing Anti-Tumor Potential at Major Cancer Conference
Circle Pharma will present promising preclinical data on its first-in-class oral macrocyclic cyclin D1-selective inhibitors at the upcoming AACR-NCI-EORTC conference. The company’s innovative approach targets cyclin D1-driven cancers through selective disruption of the cyclin D1-Rb interaction.
Circle Pharma, a clinical-stage biopharmaceutical company focused on developing targeted macrocycle therapeutics, has announced an upcoming poster presentation highlighting the significant anti-tumor potential of cyclin D1 RxL inhibition. The presentation will occur at the prestigious AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston from October 22-26, 2025.